The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 20, Issue 1, Pages 15-22
Publisher
Informa UK Limited
Online
2019-10-14
DOI
10.1080/14712598.2020.1677603
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- European cancer mortality predictions for the year 2018 with focus on colorectal cancer
- (2018) M Malvezzi et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The PLGF/c-MYC/miR-19a axis promotes metastasis and stemness in gallbladder cancer
- (2018) Huaifeng Li et al. CANCER SCIENCE
- 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?
- (2018) E Mata Velasco et al. ANNALS OF ONCOLOGY
- Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.
- (2017) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis
- (2017) Zanfeng Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer
- (2017) Sedef Hande AKTAŞ et al. Turkish Journal Of Medical Sciences
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
- (2016) Khurum Khan et al. CURRENT DRUG TARGETS
- Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness
- (2016) ELENA PAGANI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Angiogenesis and wound repair: when enough is enough
- (2016) Luisa A. DiPietro JOURNAL OF LEUKOCYTE BIOLOGY
- Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
- (2016) Rachel Riechelmann et al. Therapeutic Advances in Medical Oncology
- Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy
- (2015) Paul Ruff et al. EUROPEAN JOURNAL OF CANCER
- Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial.
- (2015) Tasha Nicholle Sims et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
- (2015) Hidetoshi Hayashi et al. Oncotarget
- Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
- (2014) M. Chiron et al. MOLECULAR CANCER THERAPEUTICS
- Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells
- (2014) Muriel Mathonnet WORLD JOURNAL OF GASTROENTEROLOGY
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
- (2013) Josep Tabernero et al. EUROPEAN JOURNAL OF CANCER
- The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
- (2013) Christopher H. Lieu et al. PLoS One
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models
- (2012) Alexandra Eichten et al. ANGIOGENESIS
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium
- (2012) Tara Karnezis et al. CANCER CELL
- A preclinical and clinical review of aflibercept for the management of cancer
- (2012) Andrew Gaya et al. CANCER TREATMENT REVIEWS
- Regorafenib for cancer
- (2012) Dirk Strumberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Premetastatic niche: ready for new therapeutic interventions?
- (2012) Alice Zoccoli et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
- (2012) J. H. Strickler et al. ONCOLOGIST
- Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases
- (2011) Nuh N. Rahbari et al. ANNALS OF SURGICAL ONCOLOGY
- Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
- (2011) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors
- (2011) Wiem Lassoued et al. CANCER BIOLOGY & THERAPY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
- (2011) Yosuke Horita et al. International Journal of Clinical Oncology
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
- (2010) Sara Van de Veire et al. CELL
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1
- (2008) Shay Sela et al. CIRCULATION RESEARCH
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes
- (2007) Vadim Tchaikovski et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search